Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

An Efficacy and Safety Evaluation of Tiotropium add-on Therapy in Patients With Severe Persistent Asthma

This study has been completed.
Information provided by:
Boehringer Ingelheim Identifier:
First received: August 16, 2006
Last updated: July 10, 2013
Last verified: July 2013
The primary objective of this study is to examine efficacy and safety of tiotropium compared to plac ebo as add-on therapy in severe asthmatics according to GINA step 4 classification

Condition Intervention Phase
Drug: tiotropium
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomised, Double-Blind, Placebo-Controlled, Crossover Efficacy and Safety Evaluation of 8-Week Treatment Periods of Two Doses [5 Mcg (2 Actuations of 2.5 Mcg) and 10 Mcg (2 Actuations of 5 Mcg)] of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler® as Add-on Therapy in Patients With Severe Persistent Asthma

Resource links provided by NLM:

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • The primary efficacy endpoint is the FEV1 response (within 3 hours post dosing) determined at the end of the 8-week treatment period

Secondary Outcome Measures:
  • FEV1 and FVC AUC 0-3h (in a subset 0-24h) PEF, use of rescue medication, daytime and nocturnal symptoms etc.

Estimated Enrollment: 115
Study Start Date: August 2006
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Outpatients of either sex, age 18 - 75 years, with at least a documented 5 year history of asthma, and a current diagnosis of severe, persistent asthma (GINA step 4), smoking history < 10 pack years and >= 1 year smoking cessation; Patients must be symptomatic

Exclusion Criteria:


  • with a recent history (i.e., six months or less) of myocardial infarction,
  • who have been hospitalized for heart failure (NYHA class III or IV) within the past year,
  • with any unstable or life threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy within the past year,
  • with malignancy for which the patient has undergone resection, radiation ther apy or chemotherapy within the last five years,
  • who have undergone thoracotomy with pulmonary resection,
  • with moderate to severe renal impairment (creatinine clearance = 50 mL/min)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00365560

Boehringer Ingelheim Investigational Site
Aalborg, Denmark
Boehringer Ingelheim Investigational Site
Aarhus C, Denmark
Boehringer Ingelheim Investigational Site
Hvidovre, Denmark
Boehringer Ingelheim Investigational Site
K?benhavn NV, Denmark
Boehringer Ingelheim Investigational Site
Odense C, Denmark
Boehringer Ingelheim Investigational Site
Gelnhausen, Germany
Boehringer Ingelheim Investigational Site
Gro?hansdorf, Germany
Boehringer Ingelheim Investigational Site
Rudersdorf, Germany
Boehringer Ingelheim Investigational Site
Wiesbaden, Germany
Boehringer Ingelheim Investigational Site
Wiesloch, Germany
lokatie Langendijk
Breda, Netherlands
Polikliniek longziekten
Eindhoven, Netherlands
Polikliniek longziekten
Groningen, Netherlands
Polikliniek Longziekten
Heerlen, Netherlands
Polikliniek longziekten
Hengelo, Netherlands
lokatie het Spittaal
Zutphen, Netherlands
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Study Coordinator Boehringer Ingelheim
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00365560     History of Changes
Other Study ID Numbers: 205.341
Study First Received: August 16, 2006
Last Updated: July 10, 2013

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Tiotropium Bromide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017